INTRODUCTION

104
In 1974, zur Hausen's researches pointed to the HPV as the major aetiological agent in 105 cervical cancer and, later, its DNA was detected in tumours found in other anogenital cases per year, and it is expected that half of these women will die of this neoplasia (5).
115
However, the difficulty to obtain enough viable wild types or recombinant HPV particles 116 has limited researches to distinct aspects of virus biology (6). All viruses enter host cells to 117 survive, replicate and evade the immune system. So far, the entry of HPV and its traffic 118 through the host cells are still not completely elucidate (7). Several studies describe this 119 6 process like a complex set of interactions among different pathways, receptors, co-receptors 120 and co-factors. In keratinocytes, HPV seems to be internalised via clathrin-dependent 121 endocytic mechanisms, but it might use alternative uptake pathways to enter cells, such as a 122 caveolae-dependent route, among others depending on viral type (6-9).
123
Currently, HPV is recognised as one of the main causes of infection-related cancer 124 worldwide, as well as the causal factor of other diseases. Infection with high-risk HPV 125 types is the aetiological cause of cervical cancer and is strongly associated with a 126 significate fraction of penile, vulvar, vaginal, anal and oropharyngeal cancers (10, 11).
127
HPVs are responsible for approximately 88% of anal cancer and 95% of anal intraepithelial 128 neoplasia grades 2/3 lesions, and 40%-50% of penis and vulvar cancers (10). In 
MATERIAL AND METHODS
144
Production of HPV16 L1/L2 VLPs
145
The production of VLPs was carried out throughout the recombinant protein expression 146 HPV16 L1 and L2 in epithelial human cells of the HEK293T lineage, cultured as 147 previously described (14) . Transfection of these cells occur in a transient way using 148 pUF3L1h and pUF3L2h vectors, which are regulated by the human cytomegalovirus 149 promoter containing complete sequences of genes L1 and L2 -a method already described 150 in detail (14, 15). In this study, besides being used to produce VLPs containing both capsid 151 proteins, HEK293T cell line was also used as a control factor on interaction assays with 152 human peripheral blood leukocytes. All assays performed in this study were analysed in 153 duplicate, being representative of at least four independent tests. EDTA -for blocking assays -, and were processed quickly, within a maximum of 2-hours 164 after collection. During this interval, they were stored at 4 o C. 
Interaction assays of leukocytes, transferrin and HPV VLPs
199
The same protocol described above was employed, with minor changes described below. competence to internalise VLPs, at around 47%-52% of cells (Table 2) . Through 301 morphological assessments, T-lymphocytes that internalised VLPs and were recognised by 302 anti-CD8 showed endocytic vesicles-like structures (Fig. 4 B, white arrow). Only 23% of 303 monocytes that were identified by anti-CD14 antibody interacted with the VLPs (Table 2) . 
Analysis of the colocalisation of VLPs and transferrin (Tf) in human PBMC
306
After 15 minutes, no colocalisation between L1 VLPs and exogenous Tf was detected 307 (Fig.7 ). Moreover, it was possible to show the internalisation of VLPs during this period.
308
After 45 minutes, colocalisation of VLPs with exogenous Tf in the cytoplasm of human 309 PBMC ( Fig. 8 and 9 , yellow arrows), and also with the TfR or CD71, was observed ( A-B, yellow arrows) suggesting that the iron pathway may be used to HPV internalisation.
311
All results were confirmed by the images' overlap, respectively (Figs. 7-9).
312
We compared the kinetics of internalization of Tf and TfR (CD71) with the colocalisation 313 of HPV16 L1/L2 VLPs produced in this study and with control HPV6, 11, 16, 18 L1 VLPs 314 derived from the Gardasil ® vaccine (Fig. 10) . After only 15 minutes of interaction it was 315 possible to observe colocalisation of TfR and Tf ( Fig. 10 A-B , purple arrows) with both 316 L1/L2 VLPs (Fig. 10 A) as well as with Gardasil L1 VLPs (Fig. 10 B) . 
